Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic

Sponsor
Virginia Commonwealth University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT06095284
Collaborator
National Institute on Aging (NIA) (NIH)
22,500,000
1
57.9
388453.6

Study Details

Study Description

Brief Summary

Since the "National Partnership to Improve Dementia Care" debuted in 2012, almost all long-stay psychoactive prescribing has been graded by CMS, which has correlated to decreased use. However, some national data suggest that while these psychoactive medications are being used less, prescriptions of mood-stabilizing antiepileptic drugs (AEDs) have increased. Unlike all other psychoactive medications, AEDs prescribed in nursing homes are not mandatorily reported to CMS or graded in a quality-measure.

Condition or Disease Intervention/Treatment Phase
  • Other: Pre-Extraction Phase
  • Other: Extraction Phase
  • Other: Post-Extraction Phase

Detailed Description

Pilot studies from Virginia suggest increases in AEDs are concentrated entirely in dementia patients with no diagnosis of epilepsy and as a purposeful unmonitored alternative to antipsychotics. AEDs are not FDA approved for dementia symptoms, have weak efficacy evidence, and convey serious risk. Increasingly it seems likely that the Partnership's debut was an inflection point where the trend towards unmonitored alternative drugs for dementia symptoms sharply increased. Early Commonwealth data hints that the COVID pandemic represents a second critical point of inflection where the existing transition towards non-superior but unreported drugs is again rapidly accelerating. All outcomes associated with this evolving prescribing phenomenon remain unknown. That said, pilot data suggests that harms may be increasing without benefit, a development with relevance to all invested in improving dementia care including patients, caregivers, and policy makers.

Study Design

Study Type:
Observational
Anticipated Enrollment :
22500000 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Prescribing Trends and Associated Outcomes of Antiepileptic Drugs and Other Psychoactive Medications in US Nursing Homes Surrounding the COVID-19 Pandemic
Actual Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jun 30, 2026
Anticipated Study Completion Date :
Jun 30, 2027

Arms and Interventions

Arm Intervention/Treatment
All nursing home residents included in the 2009-2021 MDS

Other: Pre-Extraction Phase
This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire

Other: Extraction Phase
Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire

Other: Post-Extraction Phase
Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation

Nursing home and non-nursing home residents diagnosed with an AD/ADRD condition

Other: Pre-Extraction Phase
This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire

Other: Extraction Phase
Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire

Other: Post-Extraction Phase
Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation

Outcome Measures

Primary Outcome Measures

  1. Quarterly rate of use and mean dose of AEDs in US nursing homes [The years 2009 to 2021]

    Quarterly rate of use and mean dose of AEDs in US nursing homes 2009-2021

Secondary Outcome Measures

  1. Quarterly rate of use of AEDs in US nursing homes for long-stay residents [The years 2009 to 2012]

    Quarterly rate of use of AEDs in US nursing homes for long-stay residents with and without: dementia, seizure-epilepsy, psychiatric diagnoses, neuropathic pain, an appropriate diagnosis for AED use

  2. Quarterly rate of adverse health events among US nursing home residents prescribed or not prescribed AEDs [The years 2009 to 2021]

    Quarterly rate of adverse health events among US nursing home residents prescribed or not prescribed AEDs from 2009 to 2021. Adverse health events include: Detrimental nursing home outcomes including falls, cognitive scores, functional scores, harmful behaviors, weight loss, hospice, death ER encounters (per 1000 nursing home days) Hospitalizations (per 1000 nursing home days), potentially avoidable hospitalizations, medication related hospitalizations, costs of hospital care.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All long-stay nursing home residents will be included. We define long-stay nursing home residents as all individuals residing in a nursing facility place of service for more than 100 days

  • All nursing home clinicians prescribing psychoactive drugs will be included.

Exclusion Criteria:
  • Limited to nursing home residents with continuous fee-for-service or Medicare Advantage plans as well as continuous Part D coverage.

  • Residents without continuous fee-for-service insurance (less than 3 percent of nursing home population) will be excluded.

  • Less than 0.2% of nursing home residents are children; still, this study will be restricted to those > 21 years of age.

  • Nursing home residents who are discharged before the end of the quarterly study periods will also be excluded.

  • Residents with discharges for acute hospitalizations followed by facility reentry on the same record will not be excluded.

  • Non-prescribing clinicians and clinicians that do not prescribe psychoactive medications will be excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Virginia Commonwealth University Richmond Virginia United States 23298

Sponsors and Collaborators

  • Virginia Commonwealth University
  • National Institute on Aging (NIA)

Investigators

  • Principal Investigator: Jonathan Winter, Virginia Commonwealth University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
NCT06095284
Other Study ID Numbers:
  • HM20025382
  • R01AG074358
First Posted:
Oct 23, 2023
Last Update Posted:
Oct 23, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Virginia Commonwealth University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 23, 2023